Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the drug as a lung ...

BMS, Mirati's Krazati cements lead over Amgen's Lumakras with FDA approval in colorectal cancer As for Amgen, the company’s Lumakras and Vectibix combination was granted approval to treat ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Krazati and Erbitux show significant efficacy in KRAS G12C-mutant mCRC, with ORR of 34% (BICR) and 43% (investigator review). The disease control rate was 85% (BICR) and 86% (investigator review), ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of ...

Bristol-Myers Squibb Co (NYSE:BMY) achieved double-digit revenue growth in 2024, driven by key products like BREYANZI, Krazati, Reblozyl, and Opdivo. The company successfully launched Cobenfy ...

Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the Zacks Consensus Estimate of $1.46. In the year-ago quarter, BMY posted an ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6, before market open. The Zacks Consensus Estimate for sales and ...

Pelareorep combined with modified FOLFIRINOX, with or without Tecentriq, shows an acceptable safety profile in metastatic PDAC patients. All patients experienced side effects, with some severe cases, ...